Table 5.
Categorical clinical outcomes for IL-6Ri and JAKi initiators: change from baseline to 6 months post-initiation
| Categorical outcomes | IL-6Ri initiators (N = 100) | JAKi initiators (N = 129) | IL-6Ri vs. JAKi initiatorsb | |||
|---|---|---|---|---|---|---|
| Percent response (n/N)a (95% CI) | Unadjusted OR (95% CI) | p value | Adjusted OR (95% CI)c | p value | ||
| Achievement of LDAd | 22.2 (18/81) | 10.8 (8/74) | 2.39 | 0.06 | 3.30 | 0.05 |
| (13.7, 32.8) | (4.8, 20.2) | (0.96, 5.92) | (1.01, 10.78) | |||
| Achievement of remissione | 5.6 (5/90) | 7.8 (8/102) | 0.77 | 0.65 | 1.68 | 0.53 |
| (1.8, 12.5) | (3.4, 14.9) | (0.24, 2.47) | (0.33, 8.63) | |||
| Improvement in HAQ of at least 0.3 units | 23.0 (20/87) | 30.2 (32/106) | 0.70 | 0.31 | 0.57 | 0.20 |
| (14.6, 33.2) | (21.7, 39.9) | (0.35, 1.40) | (0.24, 1.36) | |||
| Improvement of 10 + units of patient-reported pain | 44.0 (40/91) | 35.8 (38/106) | 1.25 | 0.48 | 1.12 | 0.77 |
| (33.6, 54.8) | (26.8, 45.7) | (0.67, 2.36) | (0.51, 2.47) | |||
| Improvement of 10 + units of patient-reported fatigue | 36.3 (33/91) | 32.0 (33/103) | 1.11 | 0.74 | 1.35 | 0.42 |
| (26.4, 47.0) | (23.2, 42.0) | (0.59, 2.08) | (0.65, 2.79) | |||
| Improvement of 10 + units of MDGA | 46.7 (43/92) | 37.7 (40/106) | 0.76 | 0.43 | 0.66 | 0.31 |
| (36.3, 57.4) | (28.5, 47.7) | (0.38, 1.51) | (0.29, 1.48) | |||
| Improvement of 10 + units of PtGA | 42.9 (39/91) | 34.9 (37/106) | 1.30 | 0.42 | 1.31 | 0.53 |
| (32.5, 53.7) | (25.9, 44.8) | (0.68, 2.48) | (0.56, 3.07) | |||
CI confidence interval, HAQ Health Assessment Questionnaire, IL-6Ri interleukin-6 receptor inhibitor, JAKi Janus kinase inhibitor, LDA low disease activity, MDGA Physician Global Assessment, n/N number of patients, OR odds ratio, PtGA Patient Global Assessment
aPercent response = (n/N) × 100
bBaseline values of respective outcome included as covariates along with therapy group; OR are calculated using JAKi initiators as the reference group
cAdjusted β from multivariable linear regression models represent the estimated difference in the mean change in the outcome for IL-6Ri initiators compared with JAKi initiators, after adjusting for other covariates
dAmong those in moderate or high disease activity at baseline
eAmong those in low, moderate, or high disease activity at baseline